GO:2000420 negative regulation of eosinophil extravasation: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000420 describes any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation, the movement of eosinophils from blood vessels into tissues.
• Eosinophil extravasation is a multi-step adhesion cascade involving selectins, integrins and chemokines; its negative regulation is critical for limiting allergic and inflammatory tissue damage [1,6].
• Endogenous anti-inflammatory mediators such as lipocortin 1 (annexin A1) and prostaglandins can down-regulate granulocyte and eosinophil accumulation in experimental inflammation [1,2].
• Allergen challenge studies show that eosinophil recruitment into airways is a dynamic process with defined kinetics, making negative regulation temporally and spatially controlled.
• Eosinophil adhesion to vascular cell adhesion molecule-1 (VCAM-1) via podosomes represents a specific molecular target for negative regulation of extravasation.
• Dysregulation of eosinophil extravasation is linked to asthma, allergic inflammation and irritable bowel syndrome with atypical food allergies, highlighting clinical relevance [3,4,5].
Description
Eosinophils are granulocytic leukocytes that normally reside in small numbers in the gastrointestinal tract but can rapidly accumulate in tissues during allergic and inflammatory responses [1,4]. The process by which eosinophils leave the bloodstream and enter tissues is called eosinophil extravasation, and it is a tightly controlled multi-step cascade involving rolling, adhesion, and transmigration [1,6]. GO:2000420, negative regulation of eosinophil extravasation, refers to any process that stops, prevents or reduces the frequency, rate or extent of this extravasation event. Understanding this negative regulation is important because excessive or prolonged eosinophil tissue infiltration drives pathology in asthma, allergy and other eosinophil-associated disorders [3,4,5]. Experimental models have shown that endogenous mediators such as lipocortin 1 and prostaglandins can suppress granulocyte and eosinophil accumulation, providing proof of principle that extravasation is actively down-regulated [1,2]. Moreover, kinetic studies of allergen-induced airway inflammation demonstrate that eosinophil recruitment is not a simple on/off switch but a regulated process with defined temporal windows. Researchers studying GO:2000420 therefore focus on the molecular brakes that limit eosinophil entry into tissues, with the goal of identifying therapeutic targets for inflammatory disease [1,6].
negative regulation of eosinophil extravasation At A Glance
| GO ID | GO:2000420 |
|---|---|
| GO term | negative regulation of eosinophil extravasation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Down-regulation of eosinophil movement from blood vessels into tissues |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation |
| Related process | Eosinophil extravasation (positive/upstream process) |
| Cellular context | Vascular endothelium, eosinophil adhesion machinery, chemokine signaling |
| Disease relevance | Asthma, allergic inflammation, eosinophil-associated gastrointestinal disorders |
What Is GO:2000420?
GO:2000420 is a biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation. In other words, it covers the cellular and molecular mechanisms that act as brakes on the movement of eosinophils out of blood vessels and into surrounding tissues. This includes signals that inhibit eosinophil adhesion to endothelial cells, reduce chemokine-driven activation, or promote detachment and retention in the circulation. The term is a negative regulatory process, meaning it is defined by its outcome: a decrease in eosinophil extravasation relative to a baseline state.
Why Is negative regulation of eosinophil extravasation Important in Cell Biology?
Negative regulation of eosinophil extravasation is important because it represents an endogenous braking system that prevents excessive eosinophil accumulation in tissues. Without such control, eosinophils can cause tissue damage through release of granule proteins and inflammatory mediators. Experimental evidence shows that anti-inflammatory mediators such as lipocortin 1 and prostaglandins can down-regulate granulocyte and eosinophil accumulation in vivo [1,2]. Allergen challenge studies further demonstrate that eosinophil recruitment into airways follows specific kinetics, implying that negative regulatory mechanisms operate at defined stages. Clinically, conditions such as asthma and irritable bowel syndrome with atypical food allergies involve abnormal eosinophil responses, making this process a potential therapeutic target [3,4,5]. Understanding GO:2000420 therefore informs both basic immunology and the development of anti-inflammatory strategies.
• Provides a molecular brake on eosinophil tissue infiltration, limiting allergic inflammation.
• Endogenous mediators like lipocortin 1 can suppress granulocyte and eosinophil accumulation.
• Prostaglandins down-regulate allergic plasma leakage in models of pleural eosinophilia.
• Kinetic studies show eosinophil recruitment is temporally regulated after allergen challenge.
• Eosinophil adhesion to VCAM-1 via podosomes is a specific step that can be negatively regulated.
• Dysregulation is linked to asthma and allergic airway disease [4,5].
• Atypical food allergies in irritable bowel syndrome may involve eosinophil-related mechanisms.
• Targeting negative regulation could reduce tissue damage in eosinophil-driven disorders [1,6].
• Relevant to drug development for anti-inflammatory therapies [1,5].
• Helps explain why some inflammatory responses resolve spontaneously [2,4].
What Happens During negative regulation of eosinophil extravasation?
Inhibition of eosinophil adhesion to endothelium
In simple terms: This step blocks eosinophils from sticking to blood vessel walls, so they cannot start leaving the bloodstream.
Eosinophil extravasation begins with adhesion to vascular endothelial cells, a process that can involve podosome-mediated binding to VCAM-1. Negative regulation at this stage reduces the strength or frequency of these adhesive interactions. Experimental evidence shows that endogenous mediators such as lipocortin 1 can down-regulate granulocyte and monocyte accumulation, implying inhibition of adhesion steps. By preventing stable adhesion, the cell remains in circulation and extravasation is reduced.
Suppression of chemokine-driven activation
In simple terms: This step turns down chemical signals that normally call eosinophils into tissues.
Chemokines are key drivers of leukocyte recruitment, and their modulation can reduce granulocyte and monocyte accumulation. Negative regulation of eosinophil extravasation can occur through reduced chemokine production or impaired chemokine sensing by eosinophils. Studies on allergen-induced airway inflammation show that eosinophilic cytokine production and airway inflammation follow specific kinetics, indicating that chemokine signals are subject to temporal control. Suppressing these signals limits the number of eosinophils that receive the go signal for extravasation.
Prostaglandin-mediated down-regulation
In simple terms: Prostaglandins are lipid messengers that can act as brakes on allergic leakage and eosinophil accumulation.
Prostaglandins have been implicated in the down-regulation of allergic plasma leakage in rats undergoing pleural eosinophilia. This suggests that prostaglandin pathways can negatively regulate the vascular permeability and cellular recruitment associated with eosinophil extravasation. The mechanism may involve altered endothelial barrier function or reduced eosinophil responsiveness, ultimately decreasing the rate of extravasation.
Temporal resolution of eosinophilic inflammation
In simple terms: After an allergic trigger, eosinophil influx naturally peaks and then subsides, thanks to built-in stop signals.
Kinetic studies of allergen-induced airway inflammation demonstrate that eosinophil recruitment is not sustained indefinitely; it follows a time course with defined increases and subsequent decreases. This temporal resolution reflects active negative regulation of extravasation. The process may involve changes in adhesion molecule expression, chemokine gradients, or survival signals that collectively reduce further eosinophil entry. Understanding these stop signals is essential for therapeutic mimicry.
Role of anti-inflammatory mediators
In simple terms: Natural anti-inflammatory proteins can put the brakes on eosinophil movement.
Lipocortin 1 (annexin A1) is an endogenous anti-inflammatory mediator that modulates granulocyte and monocyte accumulation in experimental inflammation. Its ability to reduce cell recruitment suggests it may also negatively regulate eosinophil extravasation. Other mediators, such as those involved in prostaglandin pathways, contribute to down-regulation of allergic plasma leakage. Together, these endogenous factors form a network that limits eosinophil tissue entry.
Key Genes Involved in GO:2000420 negative regulation of eosinophil extravasation
The following genes and proteins have been implicated in processes related to eosinophil extravasation and its negative regulation, based on experimental studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANXA1 | Mediator of anti-inflammatory effects, including down-regulation of granulocyte accumulation | Studied for its ability to inhibit leukocyte recruitment |
| VCAM1 | Endothelial adhesion molecule that binds eosinophils via podosomes | Target for blocking eosinophil adhesion and extravasation |
| ITGB1 | Integrin subunit involved in eosinophil adhesion to VCAM-1 | Potential target to reduce stable adhesion |
| ITGB2 | Integrin subunit mediating leukocyte adhesion | Involved in eosinophil adhesion steps |
| PTGS1 | Cyclooxygenase involved in prostaglandin synthesis | Prostaglandins down-regulate allergic plasma leakage |
| PTGS2 | Inducible cyclooxygenase in inflammation | May influence prostaglandin-mediated negative regulation |
| CCL11 | Eotaxin-1, chemokine that recruits eosinophils | Modulation of chemokine signals affects extravasation |
| CCR3 | Eosinophil chemokine receptor for eotaxin | Chemokine sensing is a step in extravasation |
| IL5 | Cytokine that promotes eosinophil survival and recruitment | Kinetic studies link IL5 to eosinophilic inflammation |
| IL4 | Cytokine involved in allergic inflammation | Associated with eosinophil recruitment |
| IL13 | Cytokine driving allergic airway inflammation | Linked to eosinophilic cytokine production |
| SELE | E-selectin, endothelial adhesion molecule | Mediates rolling adhesion of eosinophils |
| SELP | P-selectin, endothelial adhesion molecule | Participates in early adhesion steps |
| ICAM1 | Endothelial adhesion molecule | Supports eosinophil adhesion |
| VLA4 | Integrin complex on eosinophils | Binds VCAM-1 during extravasation |
| PECAM1 | Platelet endothelial cell adhesion molecule | Involved in transmigration |
| MMP9 | Matrix metalloproteinase | May facilitate tissue remodeling during eosinophil influx |
How Is negative regulation of eosinophil extravasation Regulated?
Negative regulation of eosinophil extravasation is itself controlled by endogenous anti-inflammatory pathways. Lipocortin 1 modulates granulocyte and monocyte accumulation, suggesting it acts as an upstream regulator of this process. Prostaglandins down-regulate allergic plasma leakage in models of pleural eosinophilia, indicating that lipid mediators can influence the extent of eosinophil extravasation. Additionally, the kinetics of allergen-induced airway inflammation show that eosinophil recruitment is temporally regulated, likely through changes in chemokine and cytokine signals. These regulatory layers ensure that eosinophil entry into tissues is balanced and self-limiting.
negative regulation of eosinophil extravasation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANXA1 | Asthma and allergic inflammation | Knockout mouse or eosinophil-specific knockout |
| VCAM1 | Eosinophil adhesion in airway inflammation | Endothelial cell-specific knockout or blocking antibodies |
| PTGS1/PTGS2 | Pleural eosinophilia and plasma leakage | Pharmacological inhibition or knockout models |
| IL5 | Eosinophilic asthma | Humanized knock-in mouse or anti-IL5 treatment models |
| CCL11 | Allergic airway disease | Chemokine knockout or overexpression models |
Asthma and allergic airway inflammation
Asthma is characterized by eosinophilic airway inflammation, and allergen challenge studies show that eosinophil recruitment follows specific kinetics. Negative regulation of eosinophil extravasation is critical for resolving inflammation; failure of these brakes may contribute to persistent eosinophilia. Experimental models of asthma have been used to test anti-asthmatic compounds that reduce eosinophil infiltration. Understanding GO:2000420 could inform therapies that enhance endogenous negative regulation.
Irritable bowel syndrome with atypical food allergies
Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E. Eosinophils are involved in gastrointestinal immune responses, and abnormal extravasation could contribute to symptoms. Negative regulation of eosinophil extravasation may be relevant to maintaining gut homeostasis. Further research is needed to link this process directly to IBS pathophysiology.
Pleural eosinophilia and allergic plasma leakage
In experimental models of pleural eosinophilia, prostaglandins down-regulate allergic plasma leakage, indicating a role for negative regulation of eosinophil extravasation in controlling vascular permeability. This suggests that therapeutic strategies mimicking prostaglandin action could reduce eosinophil-driven tissue edema. The model provides a platform to study the molecular brakes on eosinophil recruitment.
From negative regulation of eosinophil extravasation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ANXA1 negatively regulate eosinophil extravasation? | ANXA1 knockout mouse with allergen challenge |
| Is VCAM1 required for eosinophil adhesion? | VCAM1 endothelial-specific knockout or blocking antibody |
| Do prostaglandins suppress eosinophil recruitment? | PTGS1/PTGS2 knockout or inhibitor-treated rats |
| What is the kinetics of eosinophil influx after allergen? | Allergen-challenged human or animal models with time-course sampling |
| Can a lectin reduce eosinophilic inflammation? | Murine asthma model treated with D-galactose-binding lectin |
| Are atypical food allergies linked to eosinophil responses? | IBS patient biopsies and food challenge studies |
How to Study the negative regulation of eosinophil extravasation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Eosinophil counts in blood and tissue | Tracking extravasation kinetics |
| Immunohistochemistry | Tissue eosinophil infiltration | Assessing inflammation in models [2,5] |
| ELISA | Cytokine and chemokine levels | Profiling allergic responses |
| Western blot | Protein expression of adhesion molecules | Studying VCAM-1 and integrins |
| Confocal microscopy | Podosome formation and adhesion | Visualizing eosinophil-endothelial interactions |
| Gene knockout models | Causal role of specific genes | Testing ANXA1 or VCAM1 function [1,6] |
| Pharmacological inhibition | Effect of pathway inhibitors | Evaluating prostaglandin role |
Flow cytometry and cell counting
Flow cytometry can quantify eosinophil numbers in blood and tissues, providing a direct readout of extravasation. Studies of allergen-induced airway inflammation have used cell counting to track eosinophil kinetics. This method helps assess whether a candidate negative regulator reduces eosinophil tissue entry.
Immunohistochemistry and imaging
Immunohistochemistry can visualize eosinophil infiltration in tissue sections, as performed in models of pleural eosinophilia and asthma [2,5]. Imaging of adhesion molecules such as VCAM-1 and podosomes can reveal molecular details of extravasation. These techniques are essential for spatial analysis of negative regulation.
Cytokine and chemokine profiling
Measuring cytokines and chemokines in bronchoalveolar lavage or tissue homogenates helps define the inflammatory milieu. Allergen challenge studies have profiled eosinophilic cytokine production over time. Such profiling can identify which signals are suppressed during negative regulation.
Genetic and pharmacological perturbation
Knockout mice, blocking antibodies, and pharmacological inhibitors are used to test causality. For example, anti-inflammatory mediators like lipocortin 1 have been tested in experimental inflammation. Prostaglandin pathway inhibitors have been used in pleural eosinophilia models. These approaches establish whether a pathway negatively regulates extravasation.
How CRISPR Can Be Used to Study GO:2000420 negative regulation of eosinophil extravasation
Knockout
CRISPR knockout of candidate genes such as ANXA1 or VCAM1 in cell models or mice can test whether they are required for negative regulation of eosinophil extravasation. For example, ANXA1 knockout would be expected to enhance eosinophil recruitment if ANXA1 is a negative regulator. Similarly, VCAM1 knockout in endothelial cells could reduce eosinophil adhesion.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites. For instance, mutating the phosphorylation site of ANXA1 might alter its anti-inflammatory function. In VCAM1, point mutations in integrin-binding motifs could affect eosinophil adhesion. These models provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in of reporter tags or human variants can track protein localization and function. A tagged ANXA1 knock-in would allow visualization of its secretion and action during inflammation. Knock-in of disease-associated variants in genes like IL5 or CCR3 could model human eosinophilic disorders.
Overexpression
Overexpression of negative regulators such as ANXA1 or prostaglandin-synthesizing enzymes could suppress eosinophil extravasation. This approach can validate therapeutic potential. For example, overexpression of PTGS2 might increase prostaglandin production and reduce allergic plasma leakage. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports negative regulation of eosinophil extravasation Research
Researchers studying negative regulation of eosinophil extravasation-related genes often need to determine whether a candidate gene is causally involved in limiting eosinophil tissue entry. EDITGENE provides CRISPR-based services to create knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional studies of GO:2000420.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of eosinophil extravasation research.
Frequently Asked Questions About negative regulation of eosinophil extravasation
What is GO:2000420?
GO:2000420 is a Gene Ontology term for negative regulation of eosinophil extravasation, defined as any process that stops, prevents or reduces the frequency, rate or extent of eosinophil extravasation.
What is eosinophil extravasation?
Eosinophil extravasation is the movement of eosinophils from blood vessels into surrounding tissues, a multi-step process involving adhesion and transmigration [1,6].
What genes are involved in negative regulation of eosinophil extravasation?
Genes such as ANXA1, VCAM1, PTGS1, PTGS2, and chemokine-related genes like CCL11 have been implicated in modulating eosinophil recruitment [1,2,6].
How is negative regulation of eosinophil extravasation studied?
Researchers use flow cytometry, immunohistochemistry, cytokine profiling, and genetic models such as knockout mice to study this process [1,2,4].
Why is negative regulation of eosinophil extravasation important in asthma?
In asthma, excessive eosinophil infiltration causes airway inflammation; negative regulation helps resolve inflammation and limit tissue damage [4,5].
What role do prostaglandins play in eosinophil extravasation?
Prostaglandins can down-regulate allergic plasma leakage and eosinophil accumulation in experimental models.
Can CRISPR be used to study negative regulation of eosinophil extravasation?
Yes, CRISPR knockout, knock-in, and overexpression models can test the causal role of specific genes in this process [1,6].
What is the role of ANXA1 in eosinophil extravasation?
ANXA1 (lipocortin 1) is an anti-inflammatory mediator that modulates granulocyte and monocyte accumulation, potentially including eosinophils.
How does VCAM-1 relate to eosinophil extravasation?
Eosinophils adhere to VCAM-1 via podosomes, a step that can be targeted for negative regulation.
What diseases are linked to abnormal eosinophil extravasation?
Asthma, allergic inflammation, and irritable bowel syndrome with atypical food allergies have been associated with eosinophil responses [3,4,5].
Conclusion
GO:2000420, negative regulation of eosinophil extravasation, represents a critical braking mechanism that limits eosinophil tissue infiltration. Experimental evidence highlights roles for anti-inflammatory mediators like lipocortin 1, prostaglandins, and adhesion molecules such as VCAM-1 in this process [1,2,6]. Dysregulation is linked to asthma and allergic disorders, making it a promising therapeutic target [4,5]. Continued research using CRISPR models and advanced profiling will further elucidate the molecular players and their clinical potential.
References
- 1. Perretti M. 1998. Lipocortin 1 and chemokine modulation of granulocyte and monocyte accumulation in experimental inflammation.. Gen Pharmacol 31(4):545-52 PMID: 9792213
- 2. Bandeira-Melo C et al.. 1996. Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia.. Br J Pharmacol 118(8):2192-8 PMID: 8864561
- 3. Fritscher-Ravens A et al.. 2019. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E.. Gastroenterology 157(1):109-118.e5 PMID: 31100380
- 4. Gauvreau GM et al.. 1999. Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation.. Am J Respir Crit Care Med 160(2):640-7 PMID: 10430741
- 5. Rogerio AP et al.. 2007. Anti-asthmatic potential of a D-galactose-binding lectin from Synadenium carinatum latex.. Glycobiology 17(8):795-804 PMID: 17522108
- 6. Johansson MW et al.. 2004. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes.. Am J Respir Cell Mol Biol 31(4):413-22 PMID: 15220135
